title: Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
abstract: OBJECTIVE
  To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis.
  
  
  METHODS
  Outpatient hemodialysis center.
  
  
  METHODS
  Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer.
  
  
  METHODS
  Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks.
  
  
  RESULTS
  Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean +/- SD difference (estimate of bias) between assays was -1.10 +/- 1.35 mg/L. The limits of agreement (mean difference +/- 1.96 x SD) between them were -3.80-1.60 mg/L.
  
  
  CONCLUSIONS
  Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.
authors.affiliation: Department of Pharmacy, Clarian Health Partners, Inc., Indiana University Hospital, Indianapolis, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Kingery
authors.forename: K M
authors.initials: KM
authors.lastname: Sowinski
authors.forename: M A
authors.initials: MA
authors.lastname: Kraus
authors.forename: J E
authors.initials: JE
authors.lastname: Klaunig
authors.forename: B A
authors.initials: BA
authors.lastname: Mueller
mesh_terms: D000900:Anti-Bacterial Agents / Q000097:blood*; D017248:Enzyme Multiplied Immunoassay Technique; D005454:Fluorescence Polarization; D006801:Humans; D007118:Immunoassay; D014640:Vancomycin / Q000097:blood*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin